Pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage IIIB small cell lung cancer: a case report and literature review
Chemotherapy combined with immunotherapy has significantly improved survival in patients with extensive-stage small cell lung cancer (ES-SCLC), and neoadjuvant immunotherapy combined with chemotherapy has emerged as the standard treatment for those with resectable non-small cell lung cancer (NSCLC)....
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1272450/full |
| _version_ | 1797352536510824448 |
|---|---|
| author | Ting Mei Ting Mei Ting Wang Ting Wang Chuanfen Lei Dan Jiang Qinghua Zhou Qinghua Zhou |
| author_facet | Ting Mei Ting Mei Ting Wang Ting Wang Chuanfen Lei Dan Jiang Qinghua Zhou Qinghua Zhou |
| author_sort | Ting Mei |
| collection | DOAJ |
| description | Chemotherapy combined with immunotherapy has significantly improved survival in patients with extensive-stage small cell lung cancer (ES-SCLC), and neoadjuvant immunotherapy combined with chemotherapy has emerged as the standard treatment for those with resectable non-small cell lung cancer (NSCLC). However, the potential benefits of surgery following neoadjuvant immunotherapy combined with chemotherapy in locally advanced SCLC remain unclear. Herein, we report a patient diagnosed with stage IIIB SCLC, who was administered five cycles of neoadjuvant serplulimab combined with chemotherapy followed by surgery, and subsequently achieved a pathologic complete response (pCR). Within a follow-up duration of six months, the patient displayed neither recurrence nor metastasis and experienced no treatment-related adverse reactions of any grade. Based on this case, for locally advanced SCLC, neoadjuvant serplulimab combined with chemotherapy followed by surgery may present an effective, safe, and potentially curative treatment strategy. Nonetheless, further prospective studies are needed to verify our findings. |
| first_indexed | 2024-03-08T13:18:11Z |
| format | Article |
| id | doaj.art-12ac654ebe354ab7a4d710c0efe4948b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T13:18:11Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-12ac654ebe354ab7a4d710c0efe4948b2024-01-18T04:21:50ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-01-011410.3389/fimmu.2023.12724501272450Pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage IIIB small cell lung cancer: a case report and literature reviewTing Mei0Ting Mei1Ting Wang2Ting Wang3Chuanfen Lei4Dan Jiang5Qinghua Zhou6Qinghua Zhou7Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaLung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaLung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaLung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaChemotherapy combined with immunotherapy has significantly improved survival in patients with extensive-stage small cell lung cancer (ES-SCLC), and neoadjuvant immunotherapy combined with chemotherapy has emerged as the standard treatment for those with resectable non-small cell lung cancer (NSCLC). However, the potential benefits of surgery following neoadjuvant immunotherapy combined with chemotherapy in locally advanced SCLC remain unclear. Herein, we report a patient diagnosed with stage IIIB SCLC, who was administered five cycles of neoadjuvant serplulimab combined with chemotherapy followed by surgery, and subsequently achieved a pathologic complete response (pCR). Within a follow-up duration of six months, the patient displayed neither recurrence nor metastasis and experienced no treatment-related adverse reactions of any grade. Based on this case, for locally advanced SCLC, neoadjuvant serplulimab combined with chemotherapy followed by surgery may present an effective, safe, and potentially curative treatment strategy. Nonetheless, further prospective studies are needed to verify our findings.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1272450/fullsmall cell lung cancerimmunotherapyneoadjuvant therapypathological complete responseserplulimabcase report |
| spellingShingle | Ting Mei Ting Mei Ting Wang Ting Wang Chuanfen Lei Dan Jiang Qinghua Zhou Qinghua Zhou Pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage IIIB small cell lung cancer: a case report and literature review Frontiers in Immunology small cell lung cancer immunotherapy neoadjuvant therapy pathological complete response serplulimab case report |
| title | Pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage IIIB small cell lung cancer: a case report and literature review |
| title_full | Pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage IIIB small cell lung cancer: a case report and literature review |
| title_fullStr | Pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage IIIB small cell lung cancer: a case report and literature review |
| title_full_unstemmed | Pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage IIIB small cell lung cancer: a case report and literature review |
| title_short | Pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage IIIB small cell lung cancer: a case report and literature review |
| title_sort | pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage iiib small cell lung cancer a case report and literature review |
| topic | small cell lung cancer immunotherapy neoadjuvant therapy pathological complete response serplulimab case report |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1272450/full |
| work_keys_str_mv | AT tingmei pathologicalcompleteresponsetoneoadjuvanttherapywithserplulimabandchemotherapyinstageiiibsmallcelllungcanceracasereportandliteraturereview AT tingmei pathologicalcompleteresponsetoneoadjuvanttherapywithserplulimabandchemotherapyinstageiiibsmallcelllungcanceracasereportandliteraturereview AT tingwang pathologicalcompleteresponsetoneoadjuvanttherapywithserplulimabandchemotherapyinstageiiibsmallcelllungcanceracasereportandliteraturereview AT tingwang pathologicalcompleteresponsetoneoadjuvanttherapywithserplulimabandchemotherapyinstageiiibsmallcelllungcanceracasereportandliteraturereview AT chuanfenlei pathologicalcompleteresponsetoneoadjuvanttherapywithserplulimabandchemotherapyinstageiiibsmallcelllungcanceracasereportandliteraturereview AT danjiang pathologicalcompleteresponsetoneoadjuvanttherapywithserplulimabandchemotherapyinstageiiibsmallcelllungcanceracasereportandliteraturereview AT qinghuazhou pathologicalcompleteresponsetoneoadjuvanttherapywithserplulimabandchemotherapyinstageiiibsmallcelllungcanceracasereportandliteraturereview AT qinghuazhou pathologicalcompleteresponsetoneoadjuvanttherapywithserplulimabandchemotherapyinstageiiibsmallcelllungcanceracasereportandliteraturereview |